Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1954 2
1955 1
1956 2
1957 2
1958 3
1959 4
1960 1
1962 4
1963 1
1964 2
1965 5
1966 1
1967 2
1968 2
1969 2
1971 1
1972 3
1973 3
1974 1
1975 3
1976 4
1978 3
1980 2
1981 1
1982 1
1983 2
1984 1
1986 1
1987 2
1990 1
1991 1
1992 1
1993 1
1994 7
1995 3
1996 8
1997 4
1998 6
1999 2
2000 2
2001 4
2002 1
2003 4
2004 1
2005 2
2006 8
2007 2
2008 3
2009 3
2010 2
2011 1
2012 2
2013 3
2014 2
2015 3
2016 4
2017 5
2018 3
2019 1
2020 1
2021 1
2022 1
2023 2
2024 4
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Results by year

Filters applied: . Clear all
Page 1
Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies.
Tariot PN, Riviere ME, Salloway S, Burns JM, Snaedal JG, Borowsky B, Lopez CL, Liu F, Rouzade-Dominguez ML, Cazorla P, Mousseau MC, Arkuszewski M, Ricart J, Viglietta V, Sui Y, Caputo A, Langbaum JB, Reiman EM, Graf A. Tariot PN, et al. Among authors: mousseau mc. Alzheimers Dement. 2024 Nov;20(11):7745-7761. doi: 10.1002/alz.14237. Epub 2024 Sep 25. Alzheimers Dement. 2024. PMID: 39320017 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T, Hajjaji N, Antoine EC, Benderra MA, Gozy M, Foa C, Mouysset JL, Grenier J, Mousseau M, Mailliez A, Saghatchian M, Lachaier E, Desmoulins I, Hennequin A, Maes P, Loirat D, Ricci F, Diéras V, Berton D, Tiong FL, Teixeira L, Dohollou N, Lévy C, Bachelot T, Pierga JY. Petit T, et al. Among authors: mousseau m. Cancer Med. 2024 May;13(9):e7168. doi: 10.1002/cam4.7168. Cancer Med. 2024. PMID: 38733172 Free PMC article.
[Diastasic perforations].
Le Neel JC, Leborgne J, Visset J, Mousseau M. Le Neel JC, et al. Among authors: mousseau m. J Chir (Paris). 1971 Jul-Aug;102(1):65-76. J Chir (Paris). 1971. PMID: 5116670 French. No abstract available.
[Fibrous thyroiditis].
Mousseau M, Kerneis JP. Mousseau M, et al. Mem Acad Chir (Paris). 1958 May 7-14;84(14-15):459-64. Mem Acad Chir (Paris). 1958. PMID: 13551915 French. No abstract available.
Prospect for anti-HER2 receptor therapy in breast cancer.
Brand FX, Ravanel N, Gauchez AS, Pasquier D, Payan R, Fagret D, Mousseau M. Brand FX, et al. Among authors: mousseau m. Anticancer Res. 2006 Jan-Feb;26(1B):463-70. Anticancer Res. 2006. PMID: 16739306 Free article. Review.
Prospect for anti-her2 receptor therapy in breast cancer.
Brand FX, Ravanel N, Gauchez AS, Pasquier D, Payan R, Fagret D, Mousseau M. Brand FX, et al. Among authors: mousseau m. Anticancer Res. 2006 Jan-Feb;26(1B):715-22. Anticancer Res. 2006. PMID: 16739343 Free article. Review.
161 results